Immuron Reports Continued Sales Growth

Sales Performance - Global H1 sales reached AUD$4.2 million, reflecting a 5% increase compared to the prior comparative period (pcp) [1] - Q2 sales amounted to AUD$2.2 million, showing an 11% increase over the prior quarter [1] - In Australia, H1 sales were AUD$3.3 million, up 13% on pcp, with Q2 sales at AUD$1.7 million, also up 11% on the prior quarter [1] - Canadian H1 sales were AUD$56 thousand, down 85% on pcp, but Q2 sales surged to AUD$42 thousand, up 191% on the prior quarter [1] - U.S. H1 sales reached AUD$0.9 million, a 17% increase on pcp, with Q2 sales at AUD$0.4 million, up 8% on the prior quarter [1] Growth Drivers - Continued sales growth in Australia attributed to increased awareness from digital and social media marketing, same store growth, new store openings, and increased travel from South East Asia [3] - The launch of ProIBS ahead of schedule contributed to early sales opportunities, with listings secured in major pharmacy wholesalers [4] - U.S. sales growth driven by marketing initiatives including improved online presence and social media engagement [4] Future Prospects - Travelan is set to launch in Jean Coutu pharmacies in Canada in Q3 FY26, which is a leading pharmacy group in Quebec [6] - The company anticipates continued sales growth in Canada through in-store educational programs and promotions [5]